Cytotheryx, Inc.

Cytotheryx has developed a proprietary bio-incubator technology that allows the expansion of primary human hepatocytes up to a thousand-fold while maintaining their vital functions. This addresses the critical shortage of high-quality liver cells for both research and therapeutic purposes. Their technology underpins multiple potential applications including cell therapy, bioartificial liver devices, transplantation, drug metabolism studies, disease modeling, and regenerative medicine. The company collaborates with leading institutions such as Mayo Clinic to advance its mission but does not yet report late-stage clinical results or commercialized products.